Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KRRO-110 · 1 trial · 2 indications
Type, frequency, and severity of treatment-emergent adverse events (TEAEs)
| Arm | Type | Description |
|---|---|---|
| Arm 1: KRRO-110 (Part A and Part B) | EXPERIMENTAL | KRRO-110 is an RNA editing oligonucleotide encapsulated in a lipid nanoparticle (LNP) administered by intravenous (IV) infusion as a single dose in Part A (SAD), multi-dose in Part B (MAD). |
| Arm 2: Placebo (Part A only) | PLACEBO_COMPARATOR | Placebo, IV administration |
| Name | Type | Description |
|---|---|---|
| KRRO-110 | DRUG | KRRO-110 drug product, IV |
Inclusion Criteria: Part A SAD cohort Inclusion Criteria (Healthy Volunteers) * Adult male or female participants, 18 to 65 years of age * Documented PiMM genotype * Participants who are willing to and able to provide signed written informed consent PiZZ Genotype (Part A SAD and Part B MAD cohort...
KRRO-110 is an investigational small molecule being developed for the treatment of Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can lead to lung and liver disease. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
KRRO-110 is a small molecule designed to address Alpha-1 Antitrypsin Deficiency. The specific molecular target has not been disclosed in available information, so its precise mechanism of action is not publicly detailed.
KRRO-110 is being developed by Korro Bio, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol KRRO.
KRRO-110 is in Phase 1 clinical development. It is an investigational drug and has not yet received regulatory approval. The ongoing clinical trial is a Phase 1/2a study designed to evaluate the safety and tolerability of the drug.
KRRO-110 is being studied in a Phase 1/2a clinical trial with the identifier NCT06677307. This trial is a single- and multiple-dose escalation study enrolling participants with Alpha-1 Antitrypsin Deficiency, as well as healthy volunteers, at sites in Australia and New Zealand.
No alternative names for KRRO-110 have been disclosed. It is identified solely by its development code KRRO-110 and is not known to be marketed under any other name.